TABLE 1.

Inclusion and exclusion criteria for clinical drug safety drug–drug interaction (DDI) abstract selection.

Inclusion	Clinical trial DDI toxicity study: Phase I/II/III clinical trials in which drug combination and/or single drug toxicity data are evaluated and reported
	Pharmaco-epidemiological DDI study: Pharmaco-epidemiology studies in which toxicities from drug combinations are reported and compared to toxicities from a single drug
	DDI and adverse drug event (ADE) case reports: DDI-induced ADE cases in which the time sequential drug and ADE are reported in clinical settings
Exclusion	a) Clinical PK DDI study: Both single drug and drug combination exposures (i.e., pharmacokinetics) are evaluated either in patients or healthy volunteers
	b) Clinical PK PG study: The single drug exposure (i.e., pharmacokinetics) is evaluated among patients who have different genotypes in CYP450 and UGT enzymes and drug transporters
	c) In vitro PK study: Substrate depletion and metabolite formation study are for the fm data collection, and inhibition study is for the Ki data collection
	d) Drug interaction detection algorithms or software
	e) Compliance of avoiding DDIs
	f) Concordance of DDI reporting among different drug interaction knowledge base
	g) Comparison of tde performance of DDI clinical decision systems
	h) Drug–alcohol/food interactions
	i) Drug/test interactions
	j) Case report studies
	k) Review papers
	l) Cell culture and animal studies
	m) Other studies that are not related to drug interactions